MedTrace Logo

Aspirin Response in High Risk Patients With Coronary Artery Disease

NCT01383304 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 906

Last updated 2016-05-12

No results posted yet for this study

Summary

Previous studies indicate that patients with cardiovascular disease have a variable response to aspirin. Despite treatment with aspirin a large number of patients suffer a myocardial infarction. This has given rise to the phenomenon "aspirin low-responsiveness". Laboratory aspirin low-responsiveness can be defined as the failure of aspirin to inhibit platelet production of thromboxane A2 or inhibit thromboxane-dependent platelet aggregation. Whether a low platelet response to aspirin results in an increased risk of future thrombotic events is of great clinical significance, but is still unknown.

The investigators hypothesize that patients with a reduced response to aspirin, determined by platelet aggregation using the apparatus Verify Now Aspirin and Multiplate, have a higher risk of thrombosis.

The purpose of this study is to investigate whether a higher incidence of cardiovascular events is found in patients with coronary artery disease (CAD) having a reduced biochemical response to aspirin compared with CAD patients having a normal biochemical response to aspirin. In addition to CAD, all patients have at least one of the following risc factors: previous myocardial infarction, type 2 diabetes mellitus and/or renal insufficiency.

Conditions

Sponsors & Collaborators

  • Aarhus University Hospital Skejby

    collaborator OTHER

  • Danish Heart Foundation

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Anne-Mette Hvas, MD, Ph.D · Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-01-31
Completion
2017-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01383304 on ClinicalTrials.gov